Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Aclaris Therapeutics (ACRS – Research Report). The associated price target remains the same with $16.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ram Selvaraju has given his Buy rating due to a combination of factors including the promising potential of Aclaris Therapeutics’ investigational therapies and the strategic progression of their clinical trials. The initiation of the Phase 1a/1b program for ATI-052, a bispecific antibody targeting TSLP and IL-4R, is a significant step forward. This therapy is designed to enhance efficacy by simultaneously inhibiting two pathways involved in immune-modulated diseases, which could potentially offer superior treatment options compared to traditional monoclonal antibodies.
Moreover, Aclaris has multiple ongoing pipeline programs with near- and medium-term catalysts that could drive future growth. The advancement of bosakitug into a Phase 2 trial for atopic dermatitis and the ongoing Phase 2a trial of ATI-2138 in moderate-to-severe atopic dermatitis patients demonstrate the company’s robust development strategy. Additionally, preclinical work on next-generation ITK inhibitors and bispecifics further supports the long-term potential of Aclaris’ pipeline. These factors collectively underpin Selvaraju’s confidence in the company’s prospects, leading to a reiterated Buy rating and a 12-month price target of $16.